Roche’s efforts to break into the lucrative obesity market haven’t abated. The pharma giant sealed the largest deal in the space earlier this year when it announced a collaboration with Zealand Pharma ...

Roche’s move came against a backdrop of wider industry retreat from gene therapy, with Pfizer pulling its FDA-approved ...